Literature DB >> 11773040

Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization.

Susan Majka1, Paul G McGuire, Arup Das.   

Abstract

PURPOSE: Hypoxia and growth factors are postulated to be involved in the development of retinal neovascularization through the regulation of extracellular proteinase production. It has been shown that matrix metalloproteinases (MMPs) are elevated in the retina during the neovascularization process. However, the factors and mechanisms that regulate the expression of these enzymes are not well characterized. The present study examines the potential role of tumor necrosis factor (TNF)-alpha as a regulator of MMPs in the retinal neovascularization process.
METHODS: C57/Bl6 mice were treated with 75% oxygen (experimental) or room air (control) from postnatal days (P)7 through P12, followed by room air until P17. Retinas were collected at P13, P15, or P17 and total RNA analyzed for the relative level of TNFalpha, TNF receptor (p55), and TNFalpha-converting enzyme (TACE). Immunostaining was used to identify changes in TNF protein expression as well as to localize TNFalpha within specific retinal cell types. The role of TNFalpha in stimulating retinal microvascular endothelial cell (RMVEC) proteinase production was evaluated using isolated murine RMVECs grown in normoxic or hypoxic conditions. Message expression was analyzed by RT-PCR and protein expression by zymographic analysis.
RESULTS: TNFalpha mRNA was increased in the retinas of experimental animals on P13 and P15, during the early stages of retinal neovascularization. In addition to being expressed by Müller glial cells and the inner nuclear layer, additional expression was noted in the outer nuclear layer of experimental animals. No significant level of apoptosis was detected in the retina of experimental animals with retinal neovascularization. Isolated RMVECs did not significantly increase MMP production directly in response to a hypoxic stimulus, but required the presence of exogenous TNFalpha. TNFalpha increased the expression of MT1-MMP, MMP-3, and MMP-9 in these cells. The levels of TACE and p55, proteins important in mediating the response of cells to TNFalpha, were found to be increased by the angiogenic protein, vascular endothelial growth factor (VEGF), which was also elevated in the experimental retinas.
CONCLUSIONS: TNFalpha levels increase in experimental mouse retinas exposed to hypoxic stimuli. Increased production of MMPs by RMVECs does not occur directly in response to a hypoxic stimulus. These cells are responsive, however, to stimulation by TNFalpha, which enhances the production of specific members of the MMP family. VEGF also plays a role in this process through its regulation of TACE and p55 mRNA in the vascular endothelial cells. These findings support the hypothesis that these two growth factors have a role in the regulation of extracellular proteinase expression during retinal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773040

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

1.  Parstatin suppresses ocular neovascularization and inflammation.

Authors:  Hu Huang; Panagiotis Vasilakis; Xiufeng Zhong; Ji-Kui Shen; Katerina Geronatsiou; Helen Papadaki; Michael E Maragoudakis; Sotirios P Gartaganis; Stanley A Vinores; Nikos E Tsopanoglou
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

2.  Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.

Authors:  Bojun Zhao; Gill Smith; Jun Cai; Aihua Ma; Mike Boulton
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

3.  High Glucose Up-regulates ADAM17 through HIF-1α in Mesangial Cells.

Authors:  Renzhong Li; Lalita Uttarwar; Bo Gao; Martine Charbonneau; Yixuan Shi; John S D Chan; Claire M Dubois; Joan C Krepinsky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 4.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

5.  Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit.

Authors:  Shiri Zayit-Soudry; Igor Vainer; Esther Zemel; Michael Mimouni; Melvin Rabena; Dante J Pieramici; Ido Perlman; Anat Loewenstein
Journal:  Doc Ophthalmol       Date:  2017-08-19       Impact factor: 2.379

6.  TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage.

Authors:  Stanley A Vinores; Wei-Hong Xiao; Jikui Shen; Peter A Campochiaro
Journal:  J Neuroimmunol       Date:  2006-11-14       Impact factor: 3.478

Review 7.  Smoking and impaired bone healing: will activation of cholinergic anti-inflammatory pathway be the bridge?

Authors:  Yonghua Chen; Qingshan Guo; Xiaohua Pan; Ling Qin; Peng Zhang
Journal:  Int Orthop       Date:  2011-03-16       Impact factor: 3.075

8.  Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit.

Authors:  Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Alexander Charonis; Georgios Agrogiannis; Nikolaos Kavantzas; Ioannis A Vergados
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

9.  The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury.

Authors:  Semih Aydoğan; Ulkü Celiker; Peykan Türkçüoğlu; Nevin Ilhan; Nusret Akpolat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-03       Impact factor: 3.117

10.  Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation.

Authors:  Shigeo Yoshida; Ayako Yoshida; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.